Karyopharm Therapeutics Inc.
KPTINasdaqCIK 1503802HealthcareFiscal year ends Dec 31
Reports and events: 270 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2216:15 ET | 8-K | 8.01 Other events | 0001193125-26-428938 |
| 2026-10-1407:30 ET | 8-K | 8.01 Other events | 0001193125-26-421025 |
| 2026-09-1816:05 ET | 8-K | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-395517 |
| 2026-09-1107:45 ET | 8-K | 1.01 Entry into a material agreement; 2.04 Item not in the standard list; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-388621 |
| 2026-08-3108:08 ET | 8-K | 8.01 Other events | 0001193125-26-375495 |
| 2026-08-1307:40 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-347906 |
| 2026-08-1307:37 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-347897 |
| 2026-07-3108:30 ET | 8-K | 8.01 Other events | 0001193125-26-326995 |
| 2026-07-1717:01 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-307964 |
| 2026-05-2816:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001503802-26-000027 |
| 2026-05-1407:45 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-222827 |
| 2026-05-1407:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-222808 |
| 2026-04-1308:23 ET | DEF 14A | Proxy statementPeriod 2026-04-13 | 0001503802-26-000023 |
| 2026-03-2708:04 ET | 8-K | 8.01 Other events | 0001503802-26-000011 |
| 2026-03-2408:00 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-120770 |
| 2026-03-0317:57 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001503802-26-000006 |
| 2026-02-1916:06 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-059349 |
| 2026-02-1320:38 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-049397 |
| 2026-02-1207:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-047670 |
| 2026-01-1207:04 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-009738 |
| 2026-01-0916:15 ET | DEF 14A | Proxy statementPeriod 2026-02-18 | 0001193125-26-008939 |
| 2025-11-0307:14 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-261667 |
| 2025-11-0307:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-261663 |
| 2025-10-1416:11 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-239015 |
| 2025-10-0807:05 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-233983 |
| 2025-09-1116:33 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001503802-25-000006 |
| 2025-08-1107:34 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-106238 |
| 2025-08-1107:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-106236 |
| 2025-07-1107:28 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-095167 |
| 2025-05-2916:28 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-079009 |
| 2025-05-1216:14 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-069231 |
| 2025-05-1216:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-069176 |
| 2025-04-1408:15 ET | DEF 14A | Proxy statementPeriod 2025-05-28 | 0000950170-25-053511 |
| 2025-02-2416:16 ET | 8-K | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0000950170-25-025640 |
| 2025-02-1907:36 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-022765 |
| 2025-02-1907:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-022764 |
| 2025-01-3116:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-018385 |
| 2025-01-3016:06 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-017223 |
| 2025-01-1308:34 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-004591 |
| 2025-01-0207:08 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-25-000092 |
| 2024-12-1616:00 ET | DEF 14A | Proxy statementPeriod 2025-01-30 | 0000950170-24-136598 |
| 2024-12-0307:09 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-269398 |
| 2024-11-2016:11 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-262541 |
| 2024-11-0816:05 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-24-124067 |
| 2024-11-0507:47 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-121076 |
| 2024-11-0507:41 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-250984 |
| 2024-10-3107:41 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-248162 |
| 2024-09-1716:10 ET | 8-K | 3.01 Delisting notice | 0001193125-24-220534 |
| 2024-08-2916:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-209907 |
| 2024-08-0607:42 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-091210 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 29, 2026, 04:32 ET. Listed shows no prices and gives no investment advice.